Curis Inc - Asset Resilience Ratio
Curis Inc (CRIS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Curis Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Curis Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Curis Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Curis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CRIS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Curis Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Curis Inc Industry Peers by Asset Resilience Ratio
Compare Curis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Curis Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Curis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $41.27 Million | -- |
| 2023-12-31 | 38.37% | $29.65 Million | $77.28 Million | -22.23pp |
| 2022-12-31 | 60.60% | $65.97 Million | $108.85 Million | +13.86pp |
| 2021-12-31 | 46.75% | $75.87 Million | $162.30 Million | +27.72pp |
| 2020-12-31 | 19.03% | $38.88 Million | $204.36 Million | +4.46pp |
| 2019-12-31 | 14.56% | $5.11 Million | $35.11 Million | +12.87pp |
| 2018-12-31 | 1.70% | $634.00K | $37.37 Million | -28.04pp |
| 2017-12-31 | 29.74% | $21.94 Million | $73.80 Million | -2.21pp |
| 2016-12-31 | 31.94% | $18.45 Million | $57.75 Million | -19.76pp |
| 2015-12-31 | 51.70% | $49.10 Million | $94.97 Million | -15.38pp |
| 2014-12-31 | 67.08% | $42.00 Million | $62.61 Million | +6.79pp |
| 2013-12-31 | 60.29% | $48.59 Million | $80.59 Million | -0.86pp |
| 2012-12-31 | 61.15% | $42.79 Million | $69.98 Million | +60.66pp |
| 2011-12-31 | 0.49% | $235.91K | $48.18 Million | -64.22pp |
| 2010-12-31 | 64.71% | $32.77 Million | $50.65 Million | +14.91pp |
| 2009-12-31 | 49.79% | $17.98 Million | $36.10 Million | +3.04pp |
| 2008-12-31 | 46.76% | $18.69 Million | $39.98 Million | +2.04pp |
| 2007-12-31 | 44.71% | $24.06 Million | $53.82 Million | +10.61pp |
| 2006-12-31 | 34.11% | $17.83 Million | $52.27 Million | -1.84pp |
| 2005-12-31 | 35.95% | $21.90 Million | $60.91 Million | -3.72pp |
| 2004-12-31 | 39.67% | $26.83 Million | $67.63 Million | +26.37pp |
| 2003-12-31 | 13.30% | $7.41 Million | $55.74 Million | -2.16pp |
| 2002-12-31 | 15.46% | $9.65 Million | $62.44 Million | +6.36pp |
| 2001-12-31 | 9.10% | $13.17 Million | $144.76 Million | -3.30pp |
| 2000-12-31 | 12.40% | $22.65 Million | $182.68 Million | -52.04pp |
| 1999-12-31 | 64.44% | $18.62 Million | $28.89 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more